Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Kim Lauper, ACR 2022: Safety of JAK-inhibitors in rheumatoid arthritis in a real-world population

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 28th 2022

The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis compared to other biologics in a real-world population.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients.‘ (Abstract number: 0290) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. What did the ORAL surveillance study teach us about the safety profile of tofacitinib, compared to TNF-inhibitors? (0:26)
  2. What were the aims and design of your study? (1:24)
  3. What were the rates of treatment discontinuation of JAK inhibitors compared with other biologic therapies? (3:08)
  4. What were your conclusions in terms of the future use of JAK inhibitors? (5:05)

Disclosures: Kim Lauper discloses receiving grant/ research support from Galapagos, Eli Lilly, AbbVie, and Pfizer; serving on advisory boards for Pfizer; and participating in speaker’s bureaus for Viatris, Gilead-Galapgos, and Pfizer.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup